ZJYL
Jin Medical International Ltd.
Medical - Instruments & Supplies
Market Cap$344M
5Y Perf.-70.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ZJYL vs LFUS
Revenue, margins, valuation, and 5-year total return — side by side.
LFUS
Littelfuse, Inc.
Hardware, Equipment & Parts
Market Cap$11.11B
5Y Perf.+64.7%
ZJYL vs LFUS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ZJYL | LFUS |
|---|---|---|
| Industry | Medical - Instruments & Supplies | Hardware, Equipment & Parts |
| Market Cap | $344M | $11.11B |
| Revenue (TTM) | $43M | $2.49B |
| Net Income (TTM) | $5M | $-40M |
| Gross Margin | 35.8% | 38.3% |
| Operating Margin | 10.0% | 2.8% |
| Forward P/E | 93.6x | 33.8x |
| Total Debt | $12M | $946M |
| Cash & Equiv. | $8M | $563M |
ZJYL vs LFUS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ZJYL
LFUS
| Stock | Mar 23 | May 26 | Return |
|---|---|---|---|
| Jin Medical Interna… (ZJYL) | 100 | 29.5 | -70.5% |
| Littelfuse, Inc. (LFUS) | 100 | 164.7 | +64.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ZJYL vs LFUS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ZJYL leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Littelfuse, Inc. is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
ZJYL
Jin Medical International Ltd.
The Income Pick
ZJYL carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.57
- Rev growth 18.6%, EPS growth 18.7%, 3Y rev CAGR 4.2%
- Lower volatility, beta 1.57, Low D/E 40.6%, current ratio 2.50x
Best for: income & stability and growth exposure
LFUS
Littelfuse, Inc.
The Long-Run Compounder
LFUS is the clearest fit if your priority is long-term compounding.
- 317.6% 10Y total return vs ZJYL's -72.3%
- Lower P/E (33.8x vs 93.6x)
- 0.7% yield; 16-year raise streak; the other pay no meaningful dividend
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ZJYL | 18.6% revenue growth vs LFUS's 8.9% |
| Value | LFUS | Lower P/E (33.8x vs 93.6x) |
| Quality / Margins | ZJYL | 10.9% margin vs LFUS's -1.6% |
| Stability / Safety | ZJYL | Beta 1.57 vs LFUS's 1.76 |
| Dividends | LFUS | 0.7% yield; 16-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | LFUS | +132.6% vs ZJYL's -86.4% |
| Efficiency (ROA) | ZJYL | 9.7% ROA vs LFUS's -1.0%, ROIC 10.3% vs 1.0% |
ZJYL vs LFUS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
ZJYL vs LFUS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLLFUSLAGGINGZJYL
ZJYLJin Medical Internati…
1leads
LFUSLittelfuse, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs ZJYLMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
LFUS4/6
Valuation MetricsMultiples, price ratios, and targets
LFUS4/4
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ZJYL7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
LFUS6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
LFUS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
LFUS is the larger business by revenue, generating $2.5B annually — 57.9x ZJYL's $43M. ZJYL is the more profitable business, keeping 10.9% of every revenue dollar as net income compared to LFUS's -1.6%. On growth, LFUS holds the edge at +18.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ZJYLJin Medical Inter… | LFUSLittelfuse, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $43M | $2.5B |
| EBITDAEarnings before interest/tax | $5M | $227M |
| Net IncomeAfter-tax profit | $5M | -$40M |
| Free Cash FlowCash after capex | -$581,373 | $390M |
| Gross MarginGross profit ÷ Revenue | +35.8% | +38.3% |
| Operating MarginEBIT ÷ Revenue | +10.0% | +2.8% |
| Net MarginNet income ÷ Revenue | +10.9% | -1.6% |
| FCF MarginFCF ÷ Revenue | -1.4% | +15.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | -6.4% | +18.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -105.3% | +69.1% |
LFUS leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
LFUS leads this category, winning 4 of 4 comparable metrics.
Valuation Metrics
On an enterprise value basis, LFUS's 83.2x EV/EBITDA is more attractive than ZJYL's 87.3x.
| Metric | ZJYLJin Medical Inter… | LFUSLittelfuse, Inc. |
|---|---|---|
| Market CapShares × price | $344M | $11.1B |
| Enterprise ValueMkt cap + debt − cash | $348M | $11.5B |
| Trailing P/EPrice ÷ TTM EPS | 93.62x | -152.27x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 33.79x |
| PEG RatioP/E ÷ EPS growth rate | 4.48x | — |
| EV / EBITDAEnterprise value multiple | 87.30x | 83.21x |
| Price / SalesMarket cap ÷ Revenue | 14.65x | 4.66x |
| Price / BookPrice ÷ Book value/share | 12.06x | 4.53x |
| Price / FCFMarket cap ÷ FCF | — | 30.35x |
LFUS leads this category, winning 4 of 4 comparable metrics.
Profitability & Efficiency
ZJYL leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
ZJYL delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-2 for LFUS. LFUS carries lower financial leverage with a 0.39x debt-to-equity ratio, signaling a more conservative balance sheet compared to ZJYL's 0.41x. On the Piotroski fundamental quality scale (0–9), LFUS scores 5/9 vs ZJYL's 2/9, reflecting solid financial health.
| Metric | ZJYLJin Medical Inter… | LFUSLittelfuse, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | +16.9% | -1.6% |
| ROA (TTM)Return on assets | +9.7% | -1.0% |
| ROICReturn on invested capital | +10.3% | +1.0% |
| ROCEReturn on capital employed | +13.8% | +1.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 |
| Debt / EquityFinancial leverage | 0.41x | 0.39x |
| Net DebtTotal debt minus cash | $3M | $383M |
| Cash & Equiv.Liquid assets | $8M | $563M |
| Total DebtShort + long-term debt | $12M | $946M |
| Interest CoverageEBIT ÷ Interest expense | 20.63x | -0.93x |
ZJYL leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
LFUS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LFUS five years ago would be worth $17,185 today (with dividends reinvested), compared to $2,767 for ZJYL. Over the past 12 months, LFUS leads with a +132.6% total return vs ZJYL's -86.4%. The 3-year compound annual growth rate (CAGR) favors LFUS at 20.1% vs ZJYL's -26.8% — a key indicator of consistent wealth creation.
| Metric | ZJYLJin Medical Inter… | LFUSLittelfuse, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -51.1% | +68.5% |
| 1-Year ReturnPast 12 months | -86.4% | +132.6% |
| 3-Year ReturnCumulative with dividends | -60.7% | +73.3% |
| 5-Year ReturnCumulative with dividends | -72.3% | +71.8% |
| 10-Year ReturnCumulative with dividends | -72.3% | +317.6% |
| CAGR (3Y)Annualised 3-year return | -26.8% | +20.1% |
LFUS leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ZJYL and LFUS each lead in 1 of 2 comparable metrics.
Risk & Volatility
ZJYL is the less volatile stock with a 1.57 beta — it tends to amplify market swings less than LFUS's 1.76 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LFUS currently trades 93.0% from its 52-week high vs ZJYL's 12.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ZJYLJin Medical Inter… | LFUSLittelfuse, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.57x | 1.76x |
| 52-Week HighHighest price in past year | $18.00 | $475.00 |
| 52-Week LowLowest price in past year | $0.12 | $188.08 |
| % of 52W HighCurrent price vs 52-week peak | +12.2% | +93.0% |
| RSI (14)Momentum oscillator 0–100 | 53.7 | 76.2 |
| Avg Volume (50D)Average daily shares traded | 22K | 265K |
Evenly matched — ZJYL and LFUS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
LFUS is the only dividend payer here at 0.65% yield — a key consideration for income-focused portfolios.
| Metric | ZJYLJin Medical Inter… | LFUSLittelfuse, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $400.00 |
| # AnalystsCovering analysts | — | 11 |
| Dividend YieldAnnual dividend ÷ price | — | +0.7% |
| Dividend StreakConsecutive years of raises | — | 16 |
| Dividend / ShareAnnual DPS | — | $2.89 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.2% |
Insufficient data to determine a leader in this category.
Key Takeaway
LFUS leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). ZJYL leads in 1 (Profitability & Efficiency). 1 tied.
Best OverallLittelfuse, Inc. (LFUS)Leads 3 of 6 categories
Loading custom metrics...
ZJYL vs LFUS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ZJYL or LFUS a better buy right now?
For growth investors, Jin Medical International Ltd.
(ZJYL) is the stronger pick with 18. 6% revenue growth year-over-year, versus 8. 9% for Littelfuse, Inc. (LFUS). Jin Medical International Ltd. (ZJYL) offers the better valuation at 93. 6x trailing P/E, making it the more compelling value choice. Analysts rate Littelfuse, Inc. (LFUS) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ZJYL or LFUS?
Over the past 5 years, Littelfuse, Inc.
(LFUS) delivered a total return of +71. 8%, compared to -72. 3% for Jin Medical International Ltd. (ZJYL). Over 10 years, the gap is even starker: LFUS returned +317. 6% versus ZJYL's -72. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ZJYL or LFUS?
By beta (market sensitivity over 5 years), Jin Medical International Ltd.
(ZJYL) is the lower-risk stock at 1. 57β versus Littelfuse, Inc. 's 1. 76β — meaning LFUS is approximately 12% more volatile than ZJYL relative to the S&P 500. On balance sheet safety, Littelfuse, Inc. (LFUS) carries a lower debt/equity ratio of 39% versus 41% for Jin Medical International Ltd. — giving it more financial flexibility in a downturn.
04Which is growing faster — ZJYL or LFUS?
By revenue growth (latest reported year), Jin Medical International Ltd.
(ZJYL) is pulling ahead at 18. 6% versus 8. 9% for Littelfuse, Inc. (LFUS). On earnings-per-share growth, the picture is similar: Jin Medical International Ltd. grew EPS 18. 7% year-over-year, compared to -172. 5% for Littelfuse, Inc.. Over a 3-year CAGR, ZJYL leads at 4. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ZJYL or LFUS?
Jin Medical International Ltd.
(ZJYL) is the more profitable company, earning 15. 6% net margin versus -3. 0% for Littelfuse, Inc. — meaning it keeps 15. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZJYL leads at 15. 5% versus 1. 6% for LFUS. At the gross margin level — before operating expenses — ZJYL leads at 40. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ZJYL or LFUS?
In this comparison, LFUS (0.
7% yield) pays a dividend. ZJYL does not pay a meaningful dividend and should not be held primarily for income.
07Is ZJYL or LFUS better for a retirement portfolio?
For long-horizon retirement investors, Littelfuse, Inc.
(LFUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0. 7% yield, +317. 6% 10Y return). Jin Medical International Ltd. (ZJYL) carries a higher beta of 1. 57 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LFUS: +317. 6%, ZJYL: -72. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ZJYL and LFUS?
These companies operate in different sectors (ZJYL (Healthcare) and LFUS (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ZJYL is a small-cap high-growth stock; LFUS is a mid-cap quality compounder stock. LFUS pays a dividend while ZJYL does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(ZJYL: -6.4% · LFUS: 18.5%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.